<?xml version="1.0" encoding="UTF-8"?>
<p id="para0003">So far, no drugs, monoclonal antibodies or vaccines have been approved to treat human infections due to coronaviruses. Several pre-existing and potential drug candidates, including chloroquine and remdesivir, have been considered 
 <xref rid="bib0010" ref-type="bibr">[10]</xref>, 
 <xref rid="bib0011" ref-type="bibr">[11]</xref>, 
 <xref rid="bib0012" ref-type="bibr">[12]</xref>. The discovery and marketing of new compounds often require months to years. However, in the face of the global spread of COVID-19, effective interventions for severe cases of COVID-19 are urgently required. Although little is known about SARS-CoV-2, several insights may be gained from its more well-known family member, SARS-CoV 
 <xref rid="bib0011" ref-type="bibr">[11]</xref>. Here we review the literature on an existing but not approved antiviral agent, remdesivir, which exhibits promising in vitro antiviral activity and preliminary clinical experiences in the treatment of COVID-19.
</p>
